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Abstract 
Introduction: We studied	 the	characteristics	of	 the	screening	procedure	 for	alpha-1	antitrypsin	at	Nevers	Hospital	 (France),	
together	with	the	performance	of	serum	protein	gel	electrophoresis	for	the	fortuitous	detection	of	patients	with	deficiency.
Material and methods: We	carried	out	a retrospective	study	of	requests	for	alpha-1	antitrypsin	determination	referred	to	the	
laboratory	during	3	years.	We	compared	these	requests	with	the	numbers	of	patients	seen	at	the	hospital	and	requiring	screening	
according	to	international	recommendations.	In	parallel,	we	reviewed	all	the	serum	protein	gel	electrophoresis	results	obtained	
during	the	same	period.
Results: The	laboratory	received	102	direct	requests	for	alpha-1	antitrypsin	determination,	whereas	more	than	1397	patients	
presented	an	indication	for	screening.	No	case	of	alpha-1	antitrypsin	deficiency	was	detected	among	the	102	patients	screened.	In	
parallel,	5551	serum	protein	gel	electrophoresis	analyses	were	carried	out	at	the	laboratory.	A decrease	in	the	size	of	the	alpha-1	
globulin	fraction	was	detected	in	68	patients.	Seventeen	of	these	patients	underwent	alpha-1	antitrypsin	determinations	and	14	
were	found	to	have	alpha-1	antitrypsin	deficiency.
Conclusion: Alpha-1	antitrypsin	deficiency	was	more	frequently	detected	fortuitously,	by	electrophoresis,	than	through	efficient	
screening.	The	exploration	of	alpha-1	globulin	deficiencies	by	serum	protein	gel	electrophoresis	thus	appears	to	be	still	a particu-
larly	efficient	approach	to	the	detection	of	alpha-1	antitrypsin	deficiency	and	should	be	carried	out	systematically.	Furthermore,	
the	testing	of	all	patients	with	an	indication	for	screening	according	to	international	recommendations	should	be	encouraged.
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Introduction
Carl-Bertil Laurell, a biochemist at the Uni-
versity of Malmö, was one of the pioneers of the 
development of serum protein electrophoresis 
(SPE) as a diagnostic tool in medicine. In 1961, 
he introduced the use of agarose gels, in place 
of paper, as a support for the migration and se-
paration of proteins, a “standard” technique still 
widely used in medical laboratories. In 1963, he 
identified the first patients with severe deficien-
cies of alpha-1 antitrypsin (AAT), the principal 
plasma protease inhibitor, based on the absence of 
a serum alpha-1 fraction on SPE. In collaboration 
with Sten Erikson, he subsequently demonstrated 
the relationship between AAT deficiency and the 
development of emphysema [1].
Today, the biological diagnosis of AAT defi-
ciency is based on sensitive and specific quanti-
fications of plasma AAT by immunoturbidimetry 
or nephelometry, which is then followed by 
isoelectric focusing to phenotype the most com-
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mon variants, or genotyping [2]. In France, these 
examinations are carried out by a few specialized 
laboratories, but testing is accessible nationwide, 
via subcontracting through a network of hospital 
and private medical laboratories. Nevertheless, 
AAT deficiency remains underdiagnosed in Fran-
ce and worldwide, despite the existence of inter-
national recommendations for screening [2]. It is 
estimated, for example, that only 5 to 10% of the 
7,500 to 10,000 patients with the PiZ phenotype, 
the most severe form of this deficiency, have been 
identified in France [3, 4], and that this condition 
is diagnosed on average 10 years after the appe-
arance of the first symptoms [5]. In Poland, the 
number of patients with the PiZ phenotype is 
estimated to be between 4,189 and 7,000 [6].
Serum protein electrophoresis remains as re-
levant as ever and is still widely prescribed for the 
exploration of various diseases (hematological, li-
ver, renal and inflammatory diseases, for example).
The widespread use of this technique may 
still allow the fortuitous discovery of patients 
with AAT deficiency. We studied the characteri-
stics of screening for AAT deficiency at Nevers 
Hospital (NH), and the performance of SPE for 
the incidental discovery of AAT deficiency in 
patients.
Material and methods
We retrospectively reviewed all requests for 
AAT determination (± typing) received by the 
laboratory during 3 years (May 2012 to May 2015) 
(subcontracted tests), noting the reasons for the 
prescription of the tests and their results. We 
compared the number of tests performed with the 
number of patients hospitalized at the NH eligible 
for screening in accordance with international 
recommendations or already diagnosed as having 
AAT deficiency, by performing statistical queries 
in the PMSI of the hospital (PMSI, programme de 
médicalisation des systèmes d’information; the 
hospital medico-administrative database). 
In parallel, we reviewed all SPE tests perfor-
med in the laboratory over the same period. Gel 
electrophoresis was performed on a Hydrasys
-Hyrys device (Sebia). For all tests in which the 
alpha-1 globulin fraction was smaller than the 
value considered normal according to laboratory 
standards (< 1 g/L, rounded to the nearest decimal 
place), in the absence of an obvious cause (he-
patocellular insufficiency, severe undernutrition, 
protein leakage), a comment was recorded concer-
ning the possibility of AAT deficiency requiring 
confirmation by quantitative determination.
This study has been declared to the CNIL, the 
French Commission for Data Protection & Civil 
Liberties (No. 1860860).
Results 
The laboratory received 119 requests, inclu-
ding 102 direct requests for AAT determination, 
during the study period. Overall, 28 of the tests 
were performed for the exploration of liver di-
sorders, 70 for respiratory disorders (32 for em-
physema, 28 for chronic obstructive pulmonary 
disease (COPD), 5 for asthma, 5 for sleep apnea, 
and 2 for pneumothorax), 1 in the context of 
vasculitis, and 3 for unknown indications (not 
recorded). No cases of AAT deficiency were de-
tected in the 102 directly requested AAT deter-
minations. Over the same period, 1,397 patients 
admitted to the hospital had an indication for 
screening: 1,180 had COPD, 147 had pulmonary 
emphysema, 38 had partially irreversible asth-
ma, 27 had bronchiectasis of unknown etiology, 
four had anti-PR3 antibody-positive vasculitis 
and one had panniculitis. It was not possible to 
determine the number of patients with unexpla-
ined liver disease or bronchial obstruction. One 
patient had already been diagnosed with AAT 
deficiency (PiMZ).
In parallel, 5,551 SPE tests were performed 
at the laboratory, on serum samples from 4,406 
patients. The alpha-1 globulin fraction was ab-
normally small in 68 patients. In response to the 
comment added to the results concerning the pos-
sibility of a deficiency, 17 subjects underwent AAT 
assays (and typing by isoelectric focusing in cases 
of confirmed deficiency; Fig. 1). AAT deficiency 
(AAT concentration < 0.93 g/L, the reference value 
of the subcontractor laboratory) was confirmed in 
14 of the 17 patients (82%; Fig. 1). The deficiency 
phenotypes were as follows: two PiZZ, four PiSZ, 
one PiSS, five PiMZ, and two PiMS. The results 
for the alpha-1 globulin fraction and AAT deter-
mination for these 17 patients are summarized in 
Figure 1, and the characteristics of the 14 subjects 
with AAT deficiencies are presented in Table 1. 
Discussion
Screening characteristics 
The lack of detection of AAT deficiency in 
any of the 102 patients directly referred for testing 
is not entirely surprising. Despite the widespread 
acceptance of AAT deficiency as a common here-
ditary disease with a prevalence similar to that of 
cystic fibrosis, it would still only be expected to 
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Figure 1. Alpha-1	antitrypsin	concentration	vs	alpha-1	globulin	fraction	on	serum	protein	electrophoresis
Table 1. Characteristics of the 14 patients with alpha-1 antitrypsin (AAT) deficiency
Pi n Age AAT concentration (g/L) Medical history
MS 2 42-74 0,78–0,92 2:	none
MZ 5 12	to	80 0,62–0,85 3:	none
1:	controlled	asthma
1:	alcoholic	cirrhosis
S 1 43 0,59 none
SZ 4 78 0,37–0,53 1:	none
41 1:	asymptomatic	but	doubt	on	chest	x-ray
59–78 2:	chronic	obstructive	pulmonary	disease
Z 2 64–68 0,30–0,32 2:	emphysema
affect 2 to 3% of all cases of chronic obstructive 
respiratory diseases, for example [2].
Even if we take into account the known limi-
tations of epidemiological statistics derived from 
administrative databases like the PMSI (e.g. lack of 
diagnostic accuracy, lack of exhaustiveness…) [7], 
the comparison of the number of requests for 
testing sent to the laboratory with the estimated 
number of patients meeting the international 
criteria for testing confirmed the existence of 
significant underscreening at our hospital. Never-
theless, the entire range of screening indications 
was represented. Such “case-by-case” screening 
has already been reported in one-off studies for 
most French [8] and European prescribers [9]. 
Prescribing practice also appears to be highly 
heterogeneous at our hospital, with considerable 
dependence on the doctor, 68% of requests ema-
nating from a single practitioner. Nevertheless, 
4 of the 6 severe cases of AAT deficiency (PiSZ 
and PiZZ) detected in our study had clinical histo-
ries including indications for screening according 
to current international recommendations, which 
had already been present for several years. This 
finding argues for the development of systematic 
screening in accordance with these recommen-
dations at our institution.
Electrophoretic performance
The dispersion of AAT levels appeared to 
reduce with decreasing size of the alpha-1 glo-
bulin fraction on SPE in this study, although 
there were too few values available to determine 
whether this trend was significant (Fig. 1). If 
confirmed, this would suggest that SPE results 
and quantitative determinations of AAT levels are 
better correlated for the most severe deficits. The 
three patients testing positive by SPE for whom 
the deficiency was not confirmed by quantitative 
determinations all had alpha-1 globulin fractions 
just below the inclusion threshold (0.9 g/l, for 
a threshold of < 1).
Advances in Respiratory Medicine 2018, vol. 86, no. 4, pages 179–182 
182 www.journals.viamedica.pl
An analysis of the distribution of confirmed 
deficiency phenotypes within the study popula-
tion revealed that their prevalence was close to 
that estimated for the French general population, 
even higher for the phenotypes associated with the 
most severe forms of AAT deficiency, even though 
only 25% of patients (17/68) underwent quantita-
tive determinations (0.045% vs. 12.7% for PiMS, 
0.1125% vs. 2% for PiMZ, 0.0225% vs. 0.5% for 
PiSS, 0.09% vs. 0.19% for PiSZ, 0.045% vs. 0.013% 
for PiZZ). The method historically developed by 
Laurell thus appears to have performed well in 
this study for the incidental detection of severe 
AAT deficiency. These results are consistent with 
those of other published studies [10]. The develop-
ment of lesions is correlated with the severity of 
the deficiency, at least for pulmonary changes [11].
Capillary electrophoresis is now used along-
side gel electrophoresis for SPE. This technique 
yields higher values for the alpha-1 globulin frac-
tion because it detects orosomucoid (alpha-1-acid 
glycoprotein) with high sensitivity, whereas gel 
electrophoresis does not. This difference in sen-
sitivity results from the high proportion of sialic 
acid in orosomucoid, which reduces dye binding 
in agarose gels but has no effect on UV absorption 
in capillary electrophoresis [12]. It is not, therefore, 
possible to detect AAT deficiency with high sen-
sitivity solely by capillary electrophoresis-based 
quantification of the alpha-1 globulin fraction [13]. 
However, analyses of qualitative modifications 
to the peak relative to a reference plot can detect 
severe AAT deficiency (decrease in magnitude and 
flattening of the peak) and the presence of hetero-
zygous variants (splitting of the peak in two) [14].
Conclusion
In conclusion, the detection of AAT deficiency 
at our hospital is largely based on fortuitous di-
scovery using SPE, rather than efficient screening. 
The exploration of alpha-1 globulin deficiency by 
SPE is informative and should be generalized. In 
addition, the examination of all patients with indi-
cations for screening according to the international 
recommendations should be encouraged. The 
development of filter paper-based tests and of sam-
pling kits for direct mailing might facilitate such 
screening, particularly in private practice [15].
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